COVID-19
Global mortality data, country rankings, and trends for COVID-19 from 1990 to 2021.
| # | Country | Share (%) | Region |
|---|
COVID-19 is a significant contributor to the global burden of disease. This page presents data from the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease Study, showing mortality trends, country rankings, and regional patterns. Understanding the epidemiology of covid-19 helps inform public health interventions and resource allocation.
This data is sourced from the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease Study 2023, processed via Our World in Data. Values represent each cause's share of total deaths (%) unless otherwise noted. Explore related mortality data using the links below.
COVID-19, caused by SARS-CoV-2, emerged in late 2019 and caused the deadliest pandemic in over a century. By early 2024, official death tolls exceeded 7 million, while excess mortality analyses suggest the true toll may exceed 15-20 million. The disease ranges from asymptomatic infection to severe pneumonia, acute respiratory distress syndrome, and multi-organ failure. Older adults and those with chronic comorbidities (obesity, diabetes, cardiovascular disease, immunosuppression) face the highest mortality risk. COVID-19 mortality was geographically heterogeneous: the Americas, Europe, and South Asia experienced the largest death tolls in absolute terms, while some island nations and countries with early, aggressive containment measures experienced much lower mortality. The pandemic exposed deep inequities in health system capacity, access to critical care, and vaccine distribution. Long COVID — persistent symptoms lasting months or years — adds a substantial morbidity burden beyond acute mortality.
Across 210 countries, covid-19 accounts for an average of 1.2% of total deaths. Regional disparities are substantial: East Asia & Pacific has the highest regional average at 1.7%, while South Asia records the lowest at 0.5% — a 3.0-fold difference that underscores the geographic inequality in covid-19 mortality burden.
COVID-19 vaccines, developed with unprecedented speed, proved highly effective at preventing severe disease and death. mRNA vaccines (Pfizer, Moderna), viral vector vaccines (AstraZeneca, J&J), and inactivated vaccines (Sinovac, Sinopharm) formed the global immunisation portfolio. Non-pharmaceutical interventions — masking, physical distancing, ventilation improvement, and testing/isolation — reduced transmission. Antiviral treatments (Paxlovid, remdesivir) and dexamethasone reduced mortality in hospitalised patients. Pandemic preparedness investments in surveillance, genomic sequencing, and equitable vaccine access are essential for future pandemic resilience.